TOP > 外国特許検索 > IMMUNE FUNCTION INSPECTION METHOD, CANCER PATIENT CATEGORIZATION METHOD, CANCER TREATMENT EFFICACY PREDICTION METHOD, AGENT FOR INCREASING INTRACELLULAR CALCIUM ION CONCENTRATION, AGENT FOR INCREASING SELECTIVE FUNCTION OF EFFECTOR MEMORY (EM) AND EFFECTOR (EFF) IN TUMOR TISSUE, AND METHOD FOR MONITORING EFFICACY OF CANCER DRUG

IMMUNE FUNCTION INSPECTION METHOD, CANCER PATIENT CATEGORIZATION METHOD, CANCER TREATMENT EFFICACY PREDICTION METHOD, AGENT FOR INCREASING INTRACELLULAR CALCIUM ION CONCENTRATION, AGENT FOR INCREASING SELECTIVE FUNCTION OF EFFECTOR MEMORY (EM) AND EFFECTOR (EFF) IN TUMOR TISSUE, AND METHOD FOR MONITORING EFFICACY OF CANCER DRUG

外国特許コード F170009152
整理番号 (S2016-0384-N0)
掲載日 2017年8月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP005011
国際公開番号 WO 2017138660
国際出願日 平成29年2月10日(2017.2.10)
国際公開日 平成29年8月17日(2017.8.17)
優先権データ
  • 特願2016-024363 (2016.2.12) JP
  • 特願2016-204284 (2016.10.18) JP
発明の名称 (英語) IMMUNE FUNCTION INSPECTION METHOD, CANCER PATIENT CATEGORIZATION METHOD, CANCER TREATMENT EFFICACY PREDICTION METHOD, AGENT FOR INCREASING INTRACELLULAR CALCIUM ION CONCENTRATION, AGENT FOR INCREASING SELECTIVE FUNCTION OF EFFECTOR MEMORY (EM) AND EFFECTOR (EFF) IN TUMOR TISSUE, AND METHOD FOR MONITORING EFFICACY OF CANCER DRUG
発明の概要(英語) The present invention pertains to an immune function inspection method in which peripheral blood is collected from a human subject, changes in the concentration of calcium ions in peripheral blood mononuclear cells (PBMC) or CD8T cells are inspected after application of an immunostimulant, and if, after the application of the immunostimulant, there is a transient increase in the concentration of calcium ions in the PBMC or CD8T cells and then the concentration returns to the pre-stimulated state, it is determined that there is a decrease in systemic immune function, and if, after the application of the immunostimulant, there is an upward trend in the concentration of calcium ions in the PBMC or CD8T cells, it is determined that the systemic immune function is normal.
従来技術、競合技術の概要(英語) BACKGROUND ART
Application of the cancer immunotherapy, the ability to pre-immunized needs to be known.
Peptide-stimulated peripheral blood lymphocytes cultured antigen, 1-2 weeks after the lymphocytes have increased measuring cytotoxic activity against cancer cells, or, the peptides used to stimulate and re-stimulation, measures IFN γ production.
However, such a method, since 1-2 weeks of culture period is necessary, the patient does not necessarily reflect the real-time lymphocyte function. Antigen peptide-stimulated culture processes, the time to induce nonspecific lymphocyte proliferation, is often the case where a false positive result.
Patent Document 1 is, the chemotherapeutic agent is metformin has the effect of enhancing the effect of consistent, metformin is itself do not have the effect of treatment of cancer in an embodiment is shown.
Non-Patent Document 1 is, the diabetes is type 2 as a therapeutic agent in the disclosed mechanism of action of metformin.
Non-Patent Document 2 is, having an anticancer activity metformin is suggested.
Patent Document 2 is, the biguanide metformin-immune anti-diabetic agent to improve the function of CD8+T insulin are disclosed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
  • 発明者(英語)
  • UDONO, Heiichiro
  • EIKAWA, Shingo
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close